Jan 31 (Reuters) - Medical equipment maker Revvity RVTY.N forecast full-year profit and revenue for 2025 below Wall Street estimates on Friday, as it expects soft demand for its products and services used in drug research.
The company has faced challenges from reduced spending from biotech clients and smaller drug developers amid higher-for-longer interest rates.
The diagnostic products and scientific tools manufacturer forecast 2025 adjusted profit to be in the range of $4.90 to $5.00 per share, the mid-point of which is below analysts' estimates of $4.99, as per data compiled by LSEG.
Revvity expects 2025 revenue to be in the range of $2.80 billion to $2.85 billion, compared with estimates of $2.87 billion.
The company, however, beat fourth-quarter profit and revenue estimates, on the back of strong sales in its life sciences and diagnostics units.
On an adjusted basis, Revvity earned a profit of $1.42 per share, topping analysts' estimates of $1.37.
The Massachusetts-based company reported fourth-quarter revenue of $729.4 million, compared with estimates of $727.9 million.
The company's life sciences unit, which provides reagents and instruments for drug discovery, brought in revenue of $336.3 million during the quarter, compared with estimates of $327.9 million.
Sales in its diagnostic unit, which provides testing tools for processes such as genetic screening, rose 4% to $393.2 million.
Formerly known as PerkinElmer, the company divested three of its businesses in 2022 to focus on life sciences and diagnostics units.
(Reporting by Sneha S K in Bengaluru; Editing by Krishna Chandra Eluri)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。